Endothelial vascular toxicity from chemotherapeutic agents: Preclinical evidence and clinical implications

• Published in: Cancer treatment reviews Vol. 38; no. 5; pp. 473 - 483
• Main Authors: Soultati, Aspasia, Mountzios, Giannis, Avgerinou, Chrysoula, Papaxoinis, George, Pectasides, Dimitrios, Dimopoulos, Meletios-Athanassios, Papadimitriou, Christos
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.08.2012
• Subjects: Angiogenesis Inhibitors - adverse effects; Angiogenesis Inhibitors - pharmacology; Angiogenesis Inhibitors - therapeutic use; Anthracyclines - adverse effects; Antimetabolites; Antimetabolites - adverse effects; Antimetabolites - pharmacology; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Bleomycin - adverse effects; Cyclophosphamide - adverse effects; Cytotoxics; Endothelium; Endothelium, Vascular - drug effects; Flow-mediated dilatation; Hematology, Oncology and Palliative Medicine; Humans; Methotrexate - adverse effects; Nitrate-mediated dilatation; Platinum compounds; Platinum Compounds - adverse effects; Platinum Compounds - pharmacology; Taxanes; Taxoids - pharmacology; Taxoids - therapeutic use; Toxicity; Vascular endothelial growth factor; Vinca alkaloids; Vinca Alkaloids - pharmacology; Platinum compounds; Toxicity; Nitrate-mediated dilatation; Flow-mediated dilatation; Vinca alkaloids; Taxanes; Vascular endothelial growth factor; Antimetabolites; Cytotoxics; Endothelium

In cancer biology angiogenesis plays a vital role in tumour growth and its subsequent metastatic potential. By targeting the angiogenic process, a new treatment strategy was added in the clinician’s therapeutic armamentarium. On the other hand, numerous classic cytotoxic agents are currently conside...